Anthem Biosciences · NSE: ANTHEM · BSE: 544449
Q1 FY27 results · Apr–Jun 2026
Anthem Biosciences reported revenue from operations of ₹418.22 crore (down 22.6% from Q1 FY26) and net profit of ₹119.94 crore (down 11.7% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 418.22 | 540.21 | −22.6% | 610.94 | −31.5% |
| Other income | 24.89 | 22.81 | +9.1% | 51.21 | −51.4% |
| Total income | 443.11 | 563.02 | −21.3% | 662.15 | −33.1% |
| Profit before tax | 144.58 | 186.25 | −22.4% | 277.92 | −48.0% |
| Net profit for the period | 119.94 | 135.79 | −11.7% | 189.76 | −36.8% |
| EPS, basic (₹) | 2.13 | 2.43 | −12.3% | 3.38 | −37.0% |
| Net margin (%) | 28.7 | 25.1 | 31.1 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 383.84 | 538.01 | −28.7% | 582.50 | −34.1% |
| Other income | 28.60 | 27.73 | +3.1% | 60.62 | −52.8% |
| Total income | 412.44 | 565.74 | −27.1% | 643.13 | −35.9% |
| Profit before tax | 136.36 | 198.94 | −31.5% | 300.72 | −54.7% |
| Net profit for the period | 102.01 | 148.34 | −31.2% | 211.66 | −51.8% |
| EPS, basic (₹) | 1.81 | 2.65 | −31.7% | 3.77 | −52.0% |
| Net margin (%) | 26.6 | 27.6 | 36.3 |
Consolidated
- Filed with BSE
- 21 Jul 2026, 17:05 IST
- Board meeting
- 21 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 Jul 2026, 17:05 IST
- Board meeting
- 21 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE